PriceTargets.com logo

NASDAQ:AAAP - (AAAP) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$81.63 As of 02/20/2018 01:00 AM ET
+0.30 (1.20%)
Get New (AAAP) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AAAP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AAAP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for (AAAP) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $81.63.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in (AAAP). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$82.00N/A
i
10/30/2017JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
i
10/2/2017JMP SecuritiesReiterated RatingOutperform$69.00Low
i
9/1/2017Jefferies Financial GroupReiterated RatingBuy$50.00 ➝ $60.00Low
i
7/27/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$69.00High
i
7/27/2017Canaccord GenuitySet Price TargetBuy$47.00Low
i
Rating by John Newman at Canaccord Genuity
6/23/2017Jefferies Financial GroupReiterated RatingBuy$50.00Low
i
6/15/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$50.00High
i
5/31/2017Canaccord GenuitySet Price TargetBuy$47.00Low
i
Rating by John Newman at Canaccord Genuity
3/24/2017Jefferies Financial GroupReiterated RatingBuy$50.00Low
i
12/22/2016JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
i
12/21/2016Canaccord GenuityReiterated RatingBuy$47.00N/A
i
Rating by John Newman at Canaccord Genuity
11/29/2016Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
i
11/28/2016Canaccord GenuityReiterated RatingBuy$47.00N/A
i
10/18/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
10/12/2016Jefferies Financial GroupReiterated RatingBuy$45.00N/A
i
5/31/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
3/16/2016CitigroupReiterated RatingNeutral$32.00 ➝ $36.00N/A
i
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$44.00 ➝ $36.00N/A
i
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$44.00 ➝ $36.00N/A
i
(Data available from 3/4/2016 forward)
(AAAP) logo
Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.
Read More

Today's Range

Now: $81.63
$81.63
$81.63

50 Day Range

MA: N/A

52 Week Range

Now: $81.63
$35.11
$82.74

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of (AAAP)?

The following Wall Street analysts have issued research reports on (AAAP) in the last twelve months:
View the latest analyst ratings for AAAP.

What is the current price target for (AAAP)?

0 Wall Street analysts have set twelve-month price targets for (AAAP) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for (AAAP) in the next year.
View the latest price targets for AAAP.

What is the current consensus analyst rating for (AAAP)?

(AAAP) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AAAP.

What other companies compete with (AAAP)?

Other companies that are similar to (AAAP) include Acusphere, Affymax, American Oriental Bioengineering, ARYx Therapeutics, AtheroNova, China Botanic Pharmaceutical, China Dongsheng International, China Health Industries, Diadexus, ERBA Diagnostics, GelStat, Global Future City, Greenwich LifeSciences, Harbor Diversified and Imagenetix.

How do I contact (AAAP)'s investor relations team?

(AAAP)'s physical mailing address is 20 Rue Diesel, Saint Genis Pouilly I0, 01630. The company's listed phone number is 33-04-50-99-30-70 and its investor relations email address is [email protected] The official website for (AAAP) is www.adacap.com.